Learn more about our CEO and leadership’s backgrounds to see how they drive for great impact across the medical field.
Co-founder & Director
Adrian Krainer, winner of the 2019 Breakthrough Prize in Life Sciences and the 2019 RNA Society Lifetime Achievement Award, is a co-founder and director of Stoke Therapeutics. He is also the St. Giles Foundation Professor and deputy director of the Cold Spring Harbor Laboratory Cancer Center. Adrian’s fundamental and applied research on RNA splicing for over three decades directly led to the invention and development of Spinraza™ (nusinersen), the first approved therapeutic that corrects a splicing defect and a life-saving drug for infants with spinal muscular atrophy. He is a member of the American Academy of Arts and Sciences and the National Academy of Inventors. He is also a Pew Scholar in the Biomedical Sciences and a recipient of a National Institutes of Health MERIT award and New York Intellectual Property Law Association’s 2017 Inventor of the Year. Adrian was awarded the 2019 Breakthrough Prize for his work developing Spinraza™, which the prize committee described as “one of the first of a promising new breed of antisense therapies.”